CAR-T in Community Oncology Practice Houston Holmes MD MBA FACP Texas Oncology PA Baylor/Charles A Sammons Cancer Center Dallas, TXChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia The patient was a 7-year-old girl with a second recurrence of ALL diagnosed 2 years earlier. A remission with a negative test for minimal residual disease had been achieved, then she had a relapse 17 months after the original diagnosis. She had a second remission after reinduction chemotherapy, but the cancer recurred 4 months later. She did not have a response to further intensive chemotherapy, including clofarabine, etoposide, and cyclophosphamide. N Engl J Med 2013;368:1509-1518 Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia Peripheral-blood mononuclear

Join for free to read